MICROGENESYS, INC. – Trademark Portfolio

Entity Type: 03

MICROGENESYS, INC. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. The owner is based in MERIDEN, CT.

1000 RESEARCH PARKWAY

MERIDEN, CT 064507159

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MGS
MGS
Abandoned 1996
MGS
MGS
Abandoned 1991
MGSCAN
MGSCAN
Cancelled 1991
MGSTAGE
MGSTAGE
Cancelled 1991
MGSEARCH
MGSEARCH
Cancelled 1991
MGS
MGS
Cancelled 1991
VAXSYN
VAXSYN
Cancelled 1987
PRESERVE
PRESERVE
Cancelled 1985
DECYDE
DECYDE
Cancelled 1985

Trademark Classifications

MICROGENESYS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (10 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (5 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does MICROGENESYS, INC. have?

MICROGENESYS, INC. has 12 U.S. trademarks filed with the USPTO.

What trademark classes does MICROGENESYS, INC. file in?

MICROGENESYS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is MICROGENESYS, INC.'s trademark registration success rate?

MICROGENESYS, INC. has a 0% trademark registration rate, with 0 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.